Tyrosine kinase inhibitorFDA-approvedFirst-line
Crizotinib
How it works
Blocks the anaplastic lymphoma kinase (ALK) on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— ALK-positive
Efficacy
In clinical trials, around 60% of patients achieved an objective response, with median progression-free survival of approximately 10.9 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Crizotinib and Next-Generation Treatments for Lung Cancer | Lung Cancer | observational | Crizotinib achieved an overall response rate of 78.5% and a median progression-free survival of 22.4 months. | Source → |
| New Cancer Treatment Approach Uses Light to Target Tumors | Lung Cancer | lab-study | — | Source → |
| Long-term benefits of lorlatinib for lung cancer patients | Lung Cancer | phase-3 | 7-year PFS was 55% with lorlatinib and 3% with crizotinib. | Source → |
| Crizotinib May Help Reduce Pulmonary Fibrosis | Lung Cancer | animal-study | — | Source → |
| Crizotinib's Effectiveness in Lung Cancer Treatment | Lung Cancer | meta-analysis | Compared with chemotherapy, crizotinib treatment resulted in a markedly higher objective response rate (OR = 6.86; 95% CI, 4.39-10.73; p < 0.00001). | Source → |
| Pregnant Lung Cancer Patient Treated with Crizotinib During Pregnancy | Lung Cancer | observational | — | Source → |
| Taletrectinib Cost-Effectiveness in ROS1+ Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Rare Eye Inflammation Linked to Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| Crizotinib's Side Effects in Real-World Use | Lung Cancer | observational | — | Source → |
| Crizotinib Efficacy in Advanced Lung Cancer Patients with ROS1 Rearrangements | Lung Cancer | phase-2 | The overall disease control rate was 100%, and the overall response rate was 76.5%. | Source → |
| Alectinib Shows Longer Survival in Asian Patients with Advanced Lung Cancer | Lung Cancer | phase-3 | Median progression-free survival was 41.6 months with alectinib versus 11.1 months with crizotinib. | Source → |
| Rare Lung Cancer Patient Shows Long-Term Response to Combination Treatment | Lung Cancer | observational | The combination treatment resulted in a durable response of more than two years. | Source → |
| Crizotinib Shows Promise in Lung Cancer Patients with MET Gene Alterations | Lung Cancer | phase-2 | The objective response rate was 38.1% in patients with MET exon 14 skipping mutations. | Source → |
| Crizotinib's Cardiac Side Effects May Be Linked to Autophagy | Lung Cancer | animal-study | — | Source → |
| MET-Targeted Therapy Resistance in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Sequential Treatment with Crizotinib and Entrectinib for Lung Cancer | Lung Cancer | observational | The patient had a total progression-free survival of 13 months from sequential crizotinib and entrectinib therapy. | Source → |
| New Treatment Combination Helps Save Vision in Uveal Melanoma Patient | Melanoma | observational | — | Source → |
| Crizotinib's Effectiveness in Lung Cancer Patients: Real-World Evidence | Lung Cancer | observational | The median duration of treatment was 12.9 months, 13.0 months, and 14.0 months for patients who received crizotinib as first-line, second-line, and second-line or later treatment, respectively. | Source → |
| Inflammation markers linked to lung cancer treatment outcomes | Lung Cancer | phase-2 | The overall response rate was 77.2%, while 1-year OS and PFS rates were 95.0% and 93.5%, respectively. | Source → |
| ALK-positive Lung Cancer Patients Respond to Crizotinib in Spain | Lung Cancer | observational | The overall response rate was 59.3% and the median progression-free survival was 15.8 months. | Source → |
| Teenager with Lung Cancer Responds Well to Crizotinib | Lung Cancer | observational | He obtained a prolonged response with PFS of 33 months. | Source → |
| Crizotinib's Effectiveness in ROS1-Positive Lung Cancer Patients | Lung Cancer | observational | The median overall survival was 36.2 months. | Source → |
| Long-term Survival Benefits of Sequential Cancer Treatment in China | Lung Cancer | observational | Estimated 5-year OS was 68.6% in the overall population. | Source → |
| Cost-effectiveness of crizotinib in treating lung cancer | Lung Cancer | phase-3 | Crizotinib produced additional 0.885 life-years and 0.772 quality-adjusted life-years (QALYs) at an incremental cost of $238,077, producing an ICER of $273,286/QALY gained. | Source → |
| Rare Lung Cancer Gene Responds to Treatment | Lung Cancer | observational | After 3 weeks of treatment, the patient had a partial response. | Source → |
| Crizotinib and Cabozantinib Treatments Help Patient with Rare Lung Cancer Mutation | Lung Cancer | observational | The patient's disease achieved partial regression and progression-free survival lasted for 8 months, and overall survival was >12 months. | Source → |
| Resistance to Cancer Drug Crizotinib Found in Lung Cancer Patients | Lung Cancer | lab-study | — | Source → |
| Targeted Therapy for Lung Cancer: A Case Study | Lung Cancer | observational | — | Source → |
| Crizotinib May Help Some Women with Advanced Vulvar Melanoma | Melanoma | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.